Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Matthew Berryman

Nurse Practitioner, Family Bend, OR Nurse Practitioner

NPI 1730836719 CMS profile 11422737

1550 Ne 27Th St Ste 100, Bend, OR 97701

Open in the dashboard

General payments

$4,663

85 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Berryman of Bend, OR is reported in the CMS Open Payments database as having received $4,663 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,984 46
2024 General $877 25
2023 General $1,779 13
2022 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Berryman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Matthew Berryman were reported at $1,984. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Matthew Berryman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $23 $141 $44–$430 $149
2023 $1,779 $154 $49–$476 $160
2024 $877 $165 $51–$504 $164
2025 $1,984 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Silk Road Medical, Inc. $1,746 18 payments
  2. Surgenex LLC $789 16 payments
  3. Boston Scientific Corporation $742 23 payments
  4. Organogenesis Inc. $452 6 payments
  5. MIMEDX Group, Inc. $336 4 payments
  6. W. L. Gore & Associates, Inc. $175 1 payment
  7. BioWound Solutions, Inc. $90 2 payments
  8. Smith+Nephew, Inc. $79 3 payments
  9. Tactile Systems Technology Inc $42 2 payments
  10. Bolton Medical Inc $35 1 payment
  11. Other $177 9 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,601 83 payments
  2. Travel and Lodging $1,063 2 payments
Products named General payments · program years 2022–2025
  1. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,746 18 payments
  2. ENROUTE Transcarotid Stent $1,746 18 payments
  3. SurGraft $789 16 payments
  4. SurMatrix $789 16 payments
  5. ArdeoGraft $789 16 payments
  6. PelloGraft $789 16 payments
  7. RenoGraft $789 16 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $232 10 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $232 10 payments
  10. JETSTREAM SC $198 9 payments
  11. Other $1,415 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

93

Median for Nurse Practitioner: 389

Drug cost

$14,589

Median for Nurse Practitioner: $21,885

Branded share of claims

15.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $13,714
Cilostazol Generic 12 $337
Rosuvastatin Calcium Generic 11 $152
Cephalexin Generic 13 $141
Amlodipine Besylate Generic 11 $113
Ciprofloxacin Hcl Generic 16 $94
Oxycodone Hcl Generic 16 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$1,621,788

Of which drugs: $1,572,291

Medicare patients

237

Average age 75

Services billed

2,739

118 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 54%
Diabetes 37%
Ischemic heart disease 37%
Chronic kidney disease 33%
Atrial fibrillation 32%
Heart failure 31%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Membrane graft or membrane wrap, per square centimeter Q4205 Office 16 649 $686,213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record